Current Price
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company is headquartered...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OObsidian T... | OBX | $775.88M | — | — | — | — | — | — |
| 2. | LLatigo Bio... | LTGO | $869.18M | — | 2.22 | — | — | — | — |
| 3. | CCity Thera... | CTY | $911.01M | — | — | — | -589.00% | — | 14.00% |
| 4. | BBambusa Th... | BBTX | $819.66M | — | — | — | — | — | — |
| 5. | MMentari Th... | MTRI | $1.08B | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Mar 25 | Mar 26 |
|---|---|---|
Revenue | 0 | 0 |
COGS | 0 | 0 |
Gross Profit | 0 | 0 |
Gross Profit % | - | - |
| 51.28 | 52.81 | |
EBIT | -51.28 | -52.81 |
OPM % | - | - |
Non-Operating Income | 4.08 | 2.33 |
PBT | -47.2 | -50.48 |
Income Tax | 0 | 0 |
Tax Rate % | - | - |
Net Income | -47.2 | -50.48 |
NPM % | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 |
|---|---|---|
Revenue | 0 | 0 |
COGS | 0 | 0 |
Gross Profit | 0 | 0 |
Gross Profit % | - | - |
| 118.46 | 181.1 | |
EBIT | -118.46 | -181.1 |
OPM % | - | - |
Non-Operating Income | 12.31 | 17.4 |
PBT | -106.15 | -163.71 |
Income Tax | 0 | 0 |
Tax Rate % | - | - |
Net Income | -106.15 | -163.71 |
NPM % | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 |
|---|---|---|
| 35.97 | 123.08 | |
| 381.96 | 297.76 | |
| 0 | 0 | |
| 0 | 0 | |
| 26.18 | 21.05 | |
Total Assets | 444.11 | 441.89 |
| 0 | 0 | |
| 409.85 | 391.6 | |
| 0 | 0 | |
| 2.42 | 3.79 | |
| 31.84 | 46.51 | |
Total Liabilities | 444.11 | 441.89 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 |
|---|---|---|
| -93 | -125.81 | |
| 0 | 0 | |
| -87.09 | 117.52 | |
Net CFNet Cash Flow | -180.1 | -8.28 |
FCFFree Cash Flow | -93.81 | -126.16 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2023 | Dec 2024 |
|---|---|---|
| - | -40.9% | |
| - | - | |
| 21.87 | 10.78 | |
| - | 0.00 | |
Cash Conversion | 0.88 | 0.77 |
Payout Ratio | - | - |
| - | - | |
| - | - | |
| - | - | |
| 2.00 | 2.00 | |
| - | - | |
| 0.00 | 0.00 | |
| - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns First Tracks Biotherapeutics Inc, from SEC filings
No SEC ownership filings for this company yet.
First Tracks Biotherapeutics Inc's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about First Tracks Biotherapeutics Inc, scored for sentiment.